Critical reviews in oncology/hematology最新文献_第2页

Global perspective on the genetic, epigenetic, and transcriptomic basis of gallbladder cancer 胆囊癌的遗传学、表观遗传学和转录组学基础的全球视角。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-04 DOI: 10.1016/j.critrevonc.2025.104830

Doutrina Das , Pooja Singh , Manjusha Pal , Manoj Pandey , Ruhi Dixit

{"title":"Global perspective on the genetic, epigenetic, and transcriptomic basis of gallbladder cancer","authors":"Doutrina Das , Pooja Singh , Manjusha Pal , Manoj Pandey , Ruhi Dixit","doi":"10.1016/j.critrevonc.2025.104830","DOIUrl":"10.1016/j.critrevonc.2025.104830","url":null,"abstract":"<div><h3>Background</h3><div>Gallbladder cancer (GBC) is a rare but aggressive malignancy with a poor prognosis. Its pathophysiology involves environmental, microbiological, and physiological factors. Emerging evidence highlights the role of genetic, epigenetic, and transcriptomic alterations in GBC onset. This article reviews these molecular changes in GBC patients.</div></div><div><h3>Methods</h3><div>A comprehensive search of PubMed, Scopus, EMBASE, and Google Scholar was conducted for articles published up to May 2025. A total of 248 relevant studies were included in this literature review.</div></div><div><h3>Results</h3><div>This review identified 24 genes associated with GBC, with mutations impacting apoptosis, cell cycle regulation, DNA repair, and cell adhesion. Transcriptomic studies revealed alterations in coding and non-coding RNAs, emphasizing RNA-based gene regulatory networks. Epigenetic changes, including DNA methylation of tumor suppressor genes, histone acetylation, and miRNA-mediated regulation, were found to influence DNA repair, cell growth, differentiation, and apoptosis. Specific alterations in mRNAs, lncRNAs, and miRNAs were also observed.</div></div><div><h3>Conclusion</h3><div>GBC is often diagnosed at an advanced stage due to the lack of specific early signs and symptoms, with benign conditions frequently mimicking GBC. Early detection relies on identifying reliable biomarkers, which remain elusive. Ongoing research aims to discover biomarkers for early diagnosis, paving the way for improved treatment outcomes.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104830"},"PeriodicalIF":5.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of HER2 pathway in vulvar paget’s disease her2通路在外阴paget病中的作用。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-04 DOI: 10.1016/j.critrevonc.2025.104836

Giulia Pomati , Giacomo Corrado , Eleonora Palluzzi , Gaia Manna , Simona Maria Fragomeni , Alex Federico , Gaetano Lanzetta , Giovanni Scambia , Giorgia Garganese

{"title":"The role of HER2 pathway in vulvar paget’s disease","authors":"Giulia Pomati , Giacomo Corrado , Eleonora Palluzzi , Gaia Manna , Simona Maria Fragomeni , Alex Federico , Gaetano Lanzetta , Giovanni Scambia , Giorgia Garganese","doi":"10.1016/j.critrevonc.2025.104836","DOIUrl":"10.1016/j.critrevonc.2025.104836","url":null,"abstract":"<div><h3>Background</h3><div>Vulvar Paget’s disease (VPD) is an orphan neoaplasm accounting 1–2 % of vulvar malignancies. Advanced VPD is currently laking effective treatment options. Since HER2 is overexpressed in 30–40 % of VPD cases, this scoping review explores its prognostic significance and the effectiveness of HER2-targeted therapies.</div></div><div><h3>Methods</h3><div>A literature review was conducted using the PubMed and Scopus databases. The search was restricted to articles in English and human studies, incorporating the terms “extramammary Paget disease”, “vulva”, “HER2”, “anti-Her2 therapy” and “trastuzumab”. Two reviewers screened abstracts and full-text article while recording relevant data.</div></div><div><h3>Results</h3><div>Seventeen small retrospective studies on HER2 expression in VPD were evaluated. All studies assessed HER2 using IHC, while only 9 studies also employed FISH to detect gene amplification. A total of 270 patients are reported, of which 121 patients (45 %) had a 3 + or 2 + score. HER2/neu amplification was reported in 40 % of invasive tumours vs 17.5 % of non-invasive tumor. Eleven case-reports and series suggested a possible benefit of HER2-targeted therapies. To be mentioned, 4 articles reported trastuzumab combined with chemotherapy as the first-line treatment option, while trastuzumab monotherapy resulted in excellent objective response in two case reports.</div></div><div><h3>Conclusion</h3><div>Although HER2 expression in VPD represents a potential therapeutic target, current evidence is largely derived from case reports and lacks substantial clinical trial data. There is an urgent need for targeted clinical trials and expanded genomic profiling to enhance understanding of the underlying molecular mechanisms and optimize treatment strategies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104836"},"PeriodicalIF":5.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasmonic surgery: SERS-active smart nanotools reshaping intraoperative decision-making and precision therapy 等离子外科：SERS-active智能纳米工具重塑术中决策和精确治疗

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-04 DOI: 10.1016/j.critrevonc.2025.104838

Biqing Chen, Jiayin Gao, Haizhu Sun, Zhi Chen, Xiaohong Qiu

{"title":"Plasmonic surgery: SERS-active smart nanotools reshaping intraoperative decision-making and precision therapy","authors":"Biqing Chen, Jiayin Gao, Haizhu Sun, Zhi Chen, Xiaohong Qiu","doi":"10.1016/j.critrevonc.2025.104838","DOIUrl":"10.1016/j.critrevonc.2025.104838","url":null,"abstract":"<div><div>Traditional surgical procedures have long been constrained by the dual challenges of \"visual limitations\" and \"temporal blind spots,\" relying on surgeons' visual and tactile assessments to determine tumor margins, with an average missed detection rate exceeding 25 %. Intraoperative frozen pathology, requiring 30–45 min, often leads to delayed decision-making. The emergence of surface-enhanced Raman scattering (SERS) technology has catalyzed the birth of \"plasmonic surgery,\" a novel field offering revolutionary solutions to these limitations. This review systematically elucidates how SERS-active intelligent nanoplatforms, integrating molecular detection and precision therapeutic functions, are transforming intraoperative decision-making processes. Breakthrough technologies such as self-navigating SERS nanorobots and stimulus-responsive signal-amplifying probes are highlighted, alongside their applications in real-time tumor margin delineation and intraoperative molecular boundary alerts. Innovative integration of SERS with augmented reality navigation systems is discussed, demonstrating a closed-loop workflow from preoperative targeted enrichment to postoperative efficacy validation. Ethical challenges in SERS-guided intelligent surgery are also explored. Finally, future directions for next-generation SERS technologies are outlined. This review aims to provide interdisciplinary insights for surgeons, nanotechnologists, and medical device developers, advancing SERS from laboratory research to clinical practice and ultimately revolutionizing the paradigm of precision surgery.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104838"},"PeriodicalIF":5.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144571640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy, safety, and clinical landscape of adoptive cell immunotherapy in advanced renal cell carcinoma: A systematic review and meta-analysis 过继细胞免疫治疗晚期肾细胞癌的疗效、安全性和临床前景：系统回顾和荟萃分析。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-03 DOI: 10.1016/j.critrevonc.2025.104833

Xinyi Qiu , Qian Wu , Jie Zhu , Tianxiang Xu , Yuqian Feng , Shengyou Lin

{"title":"Efficacy, safety, and clinical landscape of adoptive cell immunotherapy in advanced renal cell carcinoma: A systematic review and meta-analysis","authors":"Xinyi Qiu , Qian Wu , Jie Zhu , Tianxiang Xu , Yuqian Feng , Shengyou Lin","doi":"10.1016/j.critrevonc.2025.104833","DOIUrl":"10.1016/j.critrevonc.2025.104833","url":null,"abstract":"<div><h3>Background</h3><div>Adoptive cell immunotherapy (ACI) has emerged as a promising treatment strategy for advanced (recurrent or metastatic) renal cell carcinoma (RCC), yet its clinical efficacy and safety remain unclear. This study aimed to systematically evaluate the therapeutic outcomes, safety profile, and research trends of ACI in this setting.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in PubMed, Embase, and the Cochrane Library for relevant clinical studies. A random-effects model was used for quantitative synthesis. ClinicalTrials.gov was also searched to assess ongoing research. Subgroup analyses were performed by geographic region and therapeutic strategy to explore heterogeneity. Publication bias was evaluated using prespecified statistical tests.</div></div><div><h3>Results</h3><div>A total of 1893 studies were screened, and 30 studies involving 508 patients were included. The pooled objective response rate (ORR) for ACI monotherapy (n = 12) was 12 % (95 % CI: 8–18 %), with a progressive disease rate (PDR) of 50 % (95 % CI: 38–62 %) and a stable disease response (SDR) of 35 % (95 % CI: 24–48 %). Most adverse events were mild to moderate (grade 1–2), with an overall incidence of 27 % (95 % CI: 9–56 %) for any-grade events. Subgroup analysis showed that cytokine-induced killer (CIK) cell therapy achieved the highest ORR (25 %). Among 89 registered trials, a shift since 2019 was observed from non-targeted, broad-spectrum immunotherapies to targeted approaches, with CAR-T trials comprising 60 % of recent studies.</div></div><div><h3>Conclusions</h3><div>ACI demonstrates limited efficacy and favorable safety in advanced RCC, particularly in combination strategies. Further large, well-designed trials are needed to confirm long-term benefits.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"213 ","pages":"Article 104833"},"PeriodicalIF":5.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac and vascular toxicity of amivantamab in non-small cell lung cancer (NSCLC): A systematic review 阿米万他单抗对非小细胞肺癌（NSCLC）的心脏和血管毒性：一项系统综述

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-03 DOI: 10.1016/j.critrevonc.2025.104835

Ionas Papassotiriou , Anastasios Tentolouris , Michalis Liontos , Alexandros Briasoulis , Maria Gavriatopoulou , Ioannis Ntanasis-Stathopoulos

{"title":"Cardiac and vascular toxicity of amivantamab in non-small cell lung cancer (NSCLC): A systematic review","authors":"Ionas Papassotiriou , Anastasios Tentolouris , Michalis Liontos , Alexandros Briasoulis , Maria Gavriatopoulou , Ioannis Ntanasis-Stathopoulos","doi":"10.1016/j.critrevonc.2025.104835","DOIUrl":"10.1016/j.critrevonc.2025.104835","url":null,"abstract":"<div><div>Amivantamab, a newly introduced drug for locally advanced or metastatic NSCLC in patients with EXON-20 mutation, has shown promising results for prolonging progression-free survival and overall survival. Amivantamab’s toxicities are common, especially those related to skin and infusion. However, its cardiovascular related toxicities are less examined. Therefore, the aim of this study was to perform a systematic review and concentrate available data for the cardiovascular toxicities of amivantamab in patients with NSCLC. This review was performed according to the PRISMA guidelines, and relevant studies were searched on three scientific databases, PubMed, Cochrane Library and ScienceDirect. In total, four phase-3 randomized clinical trials, three phase-1 clinical trials, and two real-world study were included in this systematic review. The results revealed that grade ≥ 3 cardiovascular toxicities are low in amivantamab monotherapy (<10 %), but their frequency increases when combined with lazertinib and overcome 20 % when amivantamab is combined with both lazertinib and chemotherapy. In addition, up to 3 % grade 5 cardiovascular events have been reported when amivantamab is combined with lazertinib. Pulmonary embolism and venous thromboembolism are the most common cardiovascular toxicities reported for amivantamab, and their risk increases when combined with lazertinib. These results indicate that amivantamab may be cardiotoxic, especially when combined with lazertininb, and cardioprotection should be considered in patients under amivantamab treatment.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"213 ","pages":"Article 104835"},"PeriodicalIF":5.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospect of interdisciplinary research on gut microbiota and colorectal cancer immunotherapy 肠道菌群与结直肠癌免疫治疗跨学科研究展望

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-03 DOI: 10.1016/j.critrevonc.2025.104832

Yao Lu , Zhen Zhang , Lining Chen , Peng Xue , Yafei Zhang , Yixuan Li , Huiyuan Guo

引用次数: 0

Exosomal noncoding RNAs in renal cell carcinoma: Mechanisms, roles, and therapeutic potential 外泌体非编码rna在肾细胞癌中的作用：机制、作用和治疗潜力

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-03 DOI: 10.1016/j.critrevonc.2025.104829

Jiaming Zhu , Ye Ding , Qiaoping Xu

{"title":"Exosomal noncoding RNAs in renal cell carcinoma: Mechanisms, roles, and therapeutic potential","authors":"Jiaming Zhu , Ye Ding , Qiaoping Xu","doi":"10.1016/j.critrevonc.2025.104829","DOIUrl":"10.1016/j.critrevonc.2025.104829","url":null,"abstract":"<div><div>Exosomes, critical mediators within the tumor microenvironment (TME), facilitate intercellular communication by transferring bioactive molecules, including noncoding RNAs (ncRNAs). These extracellular vesicles, secreted by nearly all cell types and detectable in bodily fluids, selectively encapsulate functional ncRNAs, which play pivotal roles in tumorigenesis, progression, and therapeutic resistance. In renal cell carcinoma (RCC), exosomal ncRNAs have emerged as key regulators driving tumor proliferation, metastasis, and immunosuppression through mechanisms such as activation of the MAPK pathway, promotion of epithelial-mesenchymal transition (EMT), and modulation of immune cell polarization. Notably, exosomal ncRNAs contribute to drug resistance by mediating cross-talk between cancer cells and stromal components, including fibroblasts and tumor-associated macrophages (TAMs). Their inherent stability, conferred by protective lipid bilayers, enhances their potential as non-invasive diagnostic and prognostic biomarkers. Specific ncRNAs, such as miR-210 and circSDHC, exhibit differential expression in RCC patient sera and urine, offering high diagnostic accuracy for early detection and metastasis monitoring. Furthermore, targeting exosomal ncRNA biogenesis or their downstream pathways—via engineered exosomes loaded with therapeutic RNAs or inhibitors—represents a promising strategy to overcome resistance and improve treatment efficacy. This review comprehensively delineates the mechanistic roles of exosomal ncRNAs in RCC pathogenesis, highlights their clinical utility as biomarkers, and explores innovative therapeutic approaches to disrupt ncRNA-mediated oncogenic signaling. Advancing our understanding of exosome-ncRNA dynamics may unlock novel precision therapies for RCC, addressing unmet challenges in current clinical management.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"213 ","pages":"Article 104829"},"PeriodicalIF":5.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The biological function and mechanism of action of circRNA as a potential target in colorectal cancer circRNA作为结直肠癌潜在靶点的生物学功能和作用机制。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-03 DOI: 10.1016/j.critrevonc.2025.104828

Yuzhi Gao , Chang Li , Tuo Ji , Kun Yu , Xuzhu Gao

{"title":"The biological function and mechanism of action of circRNA as a potential target in colorectal cancer","authors":"Yuzhi Gao , Chang Li , Tuo Ji , Kun Yu , Xuzhu Gao","doi":"10.1016/j.critrevonc.2025.104828","DOIUrl":"10.1016/j.critrevonc.2025.104828","url":null,"abstract":"<div><div>Colorectal cancer (CRC) is one of the most common malignancies worldwide. Its incidence continues to rise, and treatment options for advanced stages are still limited. In recent years, circular RNAs (circRNAs), a special class of non-coding RNAs, have demonstrated potential applications in cancer therapy. CircRNAs exhibit high stability and tissue specificity, and they play roles in tumorigenesis and progression through multiple mechanisms, such as acting as microRNA (miRNA) sponges, interacting with proteins, modulating transcription, and participating in signal transduction. In CRC specific circRNAs can regulate gene expression within the tumor microenvironment, thereby influencing tumor cell behavior, angiogenesis, immune evasion, and metabolic reprogramming. Moreover, circRNAs hold promise as potential diagnostic and prognostic biomarkers, as well as therapeutic targets for CRC. Although an increasing number of original studies have revealed the diverse functions of circRNAs in CRC, comprehensive reviews that synthesize these findings and relate them to clinical relevance remain scarce. This narrative review explores the latest advances in circRNA research in CRC and discusses their clinical potential as diagnostic and prognostic biomarkers, therapeutic agents, and drug targets.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"213 ","pages":"Article 104828"},"PeriodicalIF":5.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting O-GlcNAcylation in tumor-associated inflammation: From molecular mechanisms to cancer therapy 靶向o - glcn酰化在肿瘤相关炎症中的作用：从分子机制到癌症治疗

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-02 DOI: 10.1016/j.critrevonc.2025.104825

Rui Shi , Ling Gao , Shao-ming Li , Wen-hao Ren , Ke-qian Zhi

{"title":"Targeting O-GlcNAcylation in tumor-associated inflammation: From molecular mechanisms to cancer therapy","authors":"Rui Shi , Ling Gao , Shao-ming Li , Wen-hao Ren , Ke-qian Zhi","doi":"10.1016/j.critrevonc.2025.104825","DOIUrl":"10.1016/j.critrevonc.2025.104825","url":null,"abstract":"<div><div>O-GlcNAcylation is a reversible protein post-translational modification. Imbalance in the O-GlcNAcylation cycle plays a crucial role in the occurrence and development of cancer, the therapeutic potential of targeting O-GlcNAcylation in tumor remains underexplored. The inflammatory response is also closely related to the occurrence and development of tumors. Targeting inflammation-related pathways or combining them with other therapies has emerged as a pivotal strategy in cancer intervention. Future research must delve into the spatiotemporal dynamics of tumor-specific inflammatory networks to advance the development of precision therapeutic strategies, a pressing challenge that remains to be addressed in clinical practice.Therefore, exploring the mechanism of action between O-GlcNAcylation and inflammatory response is extremely important for developing new targeted therapies for cancer. The role of inflammation progression regulated by O-GlcNAcylation in the treatment of tumors is summarized, providing a theoretical basis for the development of new targeted therapies in clinical practice.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104825"},"PeriodicalIF":5.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next-Generation models of Gallbladder Carcinoma: Linking biological insights to precision medicine 下一代胆囊癌模型：将生物学洞察力与精准医学联系起来。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-07-01 DOI: 10.1016/j.critrevonc.2025.104827

Om Saswat Sahoo , Rashmi Minocha , Deepak Kumar , Arnab Nayek , Gurpreet Singh , Nidhi Bhardwaj , Sajib Sarkar , Nihar R. Nayak , Ruby Dhar , Subhradip Karmakar

{"title":"Next-Generation models of Gallbladder Carcinoma: Linking biological insights to precision medicine","authors":"Om Saswat Sahoo , Rashmi Minocha , Deepak Kumar , Arnab Nayek , Gurpreet Singh , Nidhi Bhardwaj , Sajib Sarkar , Nihar R. Nayak , Ruby Dhar , Subhradip Karmakar","doi":"10.1016/j.critrevonc.2025.104827","DOIUrl":"10.1016/j.critrevonc.2025.104827","url":null,"abstract":"<div><div>Gallbladder carcinoma (GBC) is among the most aggressive and deadly malignancies of the biliary tract, with limited early diagnosis and treatment options largely due to a poor understanding of its complex tumor biology. Effective preclinical in vitro models are essential for advancing the understanding of its complex pathobiology and improving therapeutic strategies. Recent research has expanded experimental platforms for studying GBC biology beyond conventional two-dimensional (2D) cultures to include advanced three-dimensional (3D) systems, xenograft models, and emerging technologies such as organoids, microfluidic devices, and air-liquid interface platforms. These models enable detailed investigation of tumor growth, stromal interactions, angiogenesis, invasion, and cellular motility. However, while traditional platforms have provided foundational insights into GBC biology, next-generation models incorporating immune components and patient-derived tissues offer enhanced recapitulation of tumor complexity and predictive power for therapeutic screening. This review critically examines the evolution of GBC modeling strategies, compares their strengths and limitations, and highlights the translational potential of cutting-edge approaches. Particular emphasis is placed on innovations that integrate immune components into patient-derived organoid systems, highlighting how cutting-edge technologies are driving the transition toward precision oncology for GBC. This detailed analysis seeks to guide future research efforts and encourage the creation of more efficient, individualized treatment approaches for this complex disease.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104827"},"PeriodicalIF":5.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0